Amgen

The Amgen Foundation (www. amgen.com/citizenship/overview. html) seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live and work.

unknown title 2009

Ms. Visco says the campaign has confused cancer patients who "feel used by this," and she has urged Congress to reject what she calls Amgen's "abusive" efforts.

Amgen Spends Big 2007

A trial date hasn't yet been set, and Amgen is widely expected to file for an injunction to block any launch by Teva if the FDA approves the drug.

FDA Seeks More Data on Teva Copy of Amgen's Neupogen Thomas Gryta 2010

However, a key catalyst for Amgen is the company's recent launch of osteoporosis drug Prolia, also known as denosumab, and that came in below expectations during its first full quarter of sales.

Amgen's Profit Falls 11% Thomas Gryta 2010

In response, Amgen is reducing the shelf life of Epogen to 12 months, from 36 months, for single-dose vials and to 15 months for multiple-dose vials.

Corporate Watch 2010

Might as well get rid of the alpha and beta terminology altogether and just call Amgen and Genentech today's "Daily Double".

The Big Picture 2008

A prime candidate: Amgen, which is expecting Food and Drug Administration approval of a similar drug on Sept. 28.

Update -- ImClone Loses Patent Case 2006

Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business.

unknown title 2011

Shahinian is a paid consultant to Amgen, which is seeking approval for its bone cancer drug, Xgeva, to treat certain men with advanced prostate cancer.

Yahoo! News: Business - Opinion 2011

We currently have a Neutral recommendation on Amgen, which is supported by a Zacks #3 Rank short-term "Hold" rating.

unknown title 2011